journal article·2020-08

Macrophage targeted amphotericin B nanodelivery systems against visceral leishmaniasis

Pankaj Kumar Singh, Bapi Gorain, Hira Choudhury, Sachin Kumar Singh, Pankaj Whadwa, Shilpa, Sanjeev Sahu, Monica Gulati, Prashant Kesharwani

Publisher page

Abstract

Abstract Visceral leishmaniasis (VL), a potentially fatal systemic disease caused by the protozoan Leishmania donovani and Leishmania infantum, transmitted by phlebotomine sandflies. This VL is characterized by an uneven spell of fever, substantial weight loss, liver and spleen swelling, and anemia. The presently available therapies for VL are based on pentavalent antimony and amphotericin B (AmB) formulations. The failure of the first treatment is due to its probability to form resistance followed by non-specific toxic manifestations leading to the popularity of the later one. The available different conventional formulations of AmB show substantially diverse pharmacokinetic parameters, and thus susceptible to dose-related toxicities, such as infusion-associated reactions and nephrotoxicity. The present review emphasizes various passive and active targeting approaches of AmB, along with the importance of macrophage-targeted delivery systems over the commercial liposomal and colloidal formulations.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Research on Leishmaniasis Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Vaccines for visceral leishmaniasis: a review10.1016/j.jim.2015.03.017 ↗
2. A review of preventative methods against human leishmaniasis infection10.1371/journal.pntd.0002278 ↗
3. WHO leishmaniasis control team, leishmaniasis worldwide and global estimates of its incidence10.1371/journal.pone.0035671 ↗
4. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani10.1128/AAC.00030-11 ↗
5. Visceral Leishmaniasis10.1016/j.idc.2012.03.005 ↗
6. Regulation of immunity during visceral Leishmania infection10.1186/s13071-016-1412-x ↗
7. D.J. Roberts, Hematologic Aspects of Parasitic Diseases, Hematology. (2018) 2278–2303.e6. doi:10.1016/B978-0-323-35762-3.00158-X.10.1016/B978-0-323-35762-3.00158-X ↗
8. Clinical presentation and renal evaluation of human visceral leishmaniasis (Kala-azar): a retrospective study of 57 patients in Brazil, Brazilian
9. B. Fever, Leishmaniasis (Cutaneous and Visceral), 2004.
10. F. Alves, G. Bilbe, S. Blesson, V. Goyal, S. Monnerat, C. Mowbray, G. Muthoni Ouattara, B. Pécoul, S. Rijal, J. Rode, A. Solomos, N. Strub-Wourgaft, M. Wasunna, S. Wells, E.E. Zijlstra, B. Arana, J. Alvar, Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives., Clin. Microbiol. Rev. 31 (2018) e00048–18. Doi:10.1128/CMR.00048-18.10.1128/CMR.00048-18 ↗
11. Liposomal amphotericin B and leishmaniasis: dose and response10.4103/0974-777X.62886 ↗
12. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes10.1128/AAC.42.2.352 ↗
13. Cloning of S-adenosyl-L-methionine:C-24-Δ-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes10.1128/AAC.48.7.2409-2414.2004 ↗
14. G. Kaur, B. Rajput, Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania., J. Parasitol. Res. 2014 (2014) 726328. doi:10.1155/2014/726328.10.1155/2014/726328 ↗
15. Design and development of Amphotericin B bearing polycaprolactone microparticles for macrophage targeting10.1166/jbn.2011.1196 ↗
16. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres10.1128/AAC.48.9.3246-3252.2004 ↗
17. Macrophage functions and regulation: roles in diseases and implications in therapeutics10.1155/2018/7590350 ↗
18. Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival10.1016/j.pt.2012.05.002 ↗
19. The roles of complement receptor 3 and Fcγ receptors during Leishmania phagosome maturation10.1189/jlb.0212086 ↗
20. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy10.1186/s12951-016-0193-x ↗
21. Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology10.1016/j.msec.2019.04.005 ↗
22. B. Gorain, H. Choudhury, M. Pandey, M.C.I. Mohd Amin, B. Singh, U. Gupta, P. Kesharwani, Dendrimers as Effective Carriers for the Treatment of Brain Tumor, in: Nanotechnology-Based Target. Drug Deliv. Syst. Brain Tumors, Elsevier, 2018, pp. 267–305. Doi:10.1016/B978-0-12-812218-1.00010-5.10.1016/B978-0-12-812218-1.00010-5 ↗
23. Mishra · 2017
24. The use of nanoscaffolds and dendrimers in tissue engineering10.1016/j.drudis.2016.12.007 ↗
25. The use of nanoparticles as biomaterials in dentistry
26. Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer10.1016/j.colsurfb.2016.01.048 ↗
27. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging10.1016/j.pmatsci.2019.03.003 ↗
28. Entrapment of drug-sorbate complex in submicron emulsion: a potential approach to improve antimicrobial activity in bacterial corneal infection10.1016/j.jddst.2018.12.006 ↗
29. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform10.1016/j.ijpharm.2013.10.055 ↗
30. Recent update on nanoemulgel as topical drug delivery system10.1016/j.xphs.2017.03.042 ↗
31. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care10.1016/j.intimp.2020.106417 ↗
32. P.K. Tripathi, B. Gorain, H. Choudhury, A. Srivastava, P. Kesharwani, Dendrimer entrapped microsponge gel of dithranol for effective topical treatment, Heliyon. 5 (2019) e01343. doi:10.1016/J.HELIYON.2019.E01343.10.1016/j.heliyon.2019.e01343 ↗
33. Kishore Uttam Kothule, Prashant Kesharwani, Suresh Kumar Gidwani, Paraag Gide, Development and Characterization of Chitosan Nanoparticles and Improvement of Oral Bioavailability of Poorly Water Soluble Acyclovir, Res. J. Pharm. Technol. 3 (2010) 1241–1245. http://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=3&issue=4&article=062 (accessed June 13, 2015).
34. Engineered nanoparticles against MDR in cancer: the state of the art and its prospective10.2174/1381612822666160617112111 ↗
35. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy
36. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system10.1007/s12272-013-0276-2 ↗
37. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy10.1016/j.msec.2018.05.054 ↗
38. Dynamics of endocytosis and exocytosis of poly(D, L-Lactide-co-Glycolide) nanoparticles in vascular smooth muscle cells10.1023/A:1022219003551 ↗
39. Effect of the surface modification, size, and shape on cellular uptake of nanoparticles10.1002/cbin.10459 ↗
40. B. Gorain, H. Choudhury, M. Pandey, A.B. Nair, M.C. Iqbal Mohd Amin, N. Molugulu, P.K. Deb, P.K. Tripathi, S. Khurana, R. Shukla, K. Kohli, Dendrimer-based nanocarriers in lung cancer therapy, nanotechnology-based target. Drug Deliv. Syst. Lung Cancer. (2019) 161–192. Doi:10.1016/B978-0-12-815720-6.00007-1.10.1016/B978-0-12-815720-6.00007-1 ↗
41. Polymeric mixed micelles as nanomedicines: achievements and perspectives10.1016/j.ejpb.2016.12.019 ↗
42. Polyethylenimine modified and non-modified polymeric micelles used for nasal administration of carvedilol10.1166/jbn.2015.1915 ↗
43. Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of Gemcitabine with natural polysaccharides for treatment of breast cancer
44. Mixed micelles self-assembled from block copolymers for drug delivery10.1016/j.cocis.2010.10.003 ↗
45. Pharmacokinetics and biodistribution of nanoparticles10.1021/mp800049w ↗
46. Applications of nanoparticles for anticancer drug delivery: a review10.1166/jnn.2015.10298 ↗
47. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles10.1016/j.biomaterials.2013.01.042 ↗
48. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B10.1016/j.actbio.2016.09.036 ↗
49. Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis10.1016/j.ijbiomac.2017.07.161 ↗
50. Poloxamer 407 (Pluronic® F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis10.1016/j.exppara.2016.07.005 ↗
51. Lipoamino acid-based micelles as promising delivery vehicles for monomeric amphotericin B10.1016/j.ijpharm.2015.11.034 ↗
52. Reformulation of fungizone by PEG-DSPE micelles: deaggregation and detoxification of amphotericin B10.1007/s11095-016-1948-7 ↗
53. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics10.1016/j.ejps.2012.12.006 ↗
54. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy10.1016/j.ijpharm.2017.07.018 ↗
55. Curcumin loaded Poly (amidoamine) dendrimer-plamitic acid core-shell nanoparticles as anti-stress therapeutics
56. Recent advances in folic acid engineered nanocarriers for treatment of breast cancer
57. Polymeric nanoparticles: the future of nanomedicine10.1002/wnan.1364 ↗
58. Recent advances in self-assembled nanoparticles for drug delivery
59. Bioinspired calcium phosphate nanoparticles featuring as efficient carrier and prompter for macrophage intervention in experimental leishmaniasis10.1007/s11095-016-1985-2 ↗
60. Macrophage-targeted chitosan anchored PLGA nanoparticles bearing doxorubicin and amphotericin B against visceral leishmaniasis10.1039/C6RA06007B ↗
61. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies10.2217/nnm.14.182 ↗
62. Development of targeted 1,2-diacyl-sn-glycero-3-phospho- l -serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis10.1517/17425247.2014.889678 ↗
63. Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis10.1007/s11095-014-1571-4 ↗
64. Development of 4-sulfated N -acetyl galactosamine anchored chitosan nanoparticles: a dual strategy for effective management of Leishmaniasis10.1016/j.colsurfb.2015.08.037 ↗
65. Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis10.1016/j.msec.2017.02.145 ↗
66. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity10.1016/j.exppara.2018.07.003 ↗
67. A.K. de O.C. Medeiros, C. de C. Gomes, M.L.Q. de A. Amaral, L.D.G. de Medeiros, I. Medeiros, D.L. Porto, C.F.S. Aragão, B.L.L. Maciel, A.H. de A. Morais, T.S. Passos, Nanoencapsulation improved water solubility and color stability of carotenoids extracted from Cantaloupe melon (Cucumis melo L.), Food Chem. 270 (2019) 562–572. Doi:10.1016/J.FOODCHEM.2018.07.099.10.1016/j.foodchem.2018.07.099 ↗
68. Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases10.2147/DDDT.S133344 ↗
69. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity
70. The study of size and stability of n-butylcyanoacrylate nanocapsule suspensions encapsulating green grass fragrance10.1088/1757-899X/292/1/012094 ↗
71. Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response10.1016/j.ijbiomac.2015.04.043 ↗
72. Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responses
73. Overexpressed macrophage mannose receptor targeted nanocapsules- mediated cargo delivery approach for eradication of resident parasite: in vitro and in vivo studies
74. Pessoa de Andrade Feitosa, F. Martín Goycoolea, R.C. Monteiro de Paula, Nanocapsules of Sterculia striata acetylated polysaccharide as a potential monomeric amphotericin B delivery matrix10.1016/j.ijbiomac.2019.02.076 ↗
75. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates10.1016/j.jconrel.2017.11.036 ↗
76. Solid lipid nanoparticle-based drug delivery for lung cancer, nanotechnology-based target
77. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art10.1016/j.ejpb.2013.08.013 ↗
78. Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs10.15171/apb.2015.022 ↗
79. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells10.7150/thno.10804 ↗
80. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles10.1007/s12010-014-1084-y ↗
81. Development and performance evaluation of amphotericin B transfersomes against resistant and sensitive clinical isolates of visceral leishmaniasis10.1166/jbn.2010.1121 ↗
82. Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations10.1080/03639045.2019.1569023 ↗
83. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations10.1080/03639045.2018.1492606 ↗
84. Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B10.1080/10837450.2018.1515225 ↗
85. Lipid-core nanocapsules increase the oral efficacy of quercetin in cutaneous leishmaniasis10.1017/S003118201700097X ↗
86. Liposome-based drug delivery for lung cancer, nanotechnology-based target
87. Nanoneuromedicine for management of neurodegenerative disorder10.1016/j.jddst.2018.12.021 ↗
88. An update on pharmacotherapy for leishmaniasis10.1517/14656566.2015.973850 ↗
89. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis10.1016/j.exppara.2018.02.003 ↗
90. Liposomal Amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis10.2165/00003495-199855040-00008 ↗
91. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice10.3109/10611869308996089 ↗
92. Chemotherapy of leishmaniasis: present challenges10.1017/S0031182016002523 ↗
93. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses10.4049/jimmunol.181.2.1386 ↗
94. Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis10.3109/08982104.2011.575381 ↗
95. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOMETM10, a new liposomal amphotericin B10.1186/s12879-015-0928-6 ↗
96. Single-dose indigenous liposomal amphotericin B in the treatment of indian visceral leishmaniasis: a phase 2 study10.4269/ajtmh.14-0259 ↗
97. Emulsomes: An emerging vesicular drug delivery system10.4103/0973-8398.102930 ↗
98. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis10.1080/10611860701453836 ↗
99. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes10.1093/jac/dkr002 ↗
100. An oral formulation of Amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis10.1093/infdis/jir735 ↗